Skip to main content
. 2014 Mar 31;58(11):1507–1514. doi: 10.1093/cid/ciu128

Figure 1.

Figure 1.

Two-way sensitivity analysis on cost and probability of recurrent Clostridium difficile infection with initial fidaxomicin treatment. Strategies were considered cost-effective at a willingness-to-pay threshold of $50 000 per quality-adjusted life-year. The smaller shaded area represents the most cost-effective strategy at any given cost and efficacy of fidaxomicin. Abbreviations: CDI, Clostridium difficile infection; FMT, fecal microbiota transplant.